Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers.

被引：0
|
作者：
Reynolds, C.
Vaidyanathan, S.
Dieterich, H. A.
Yeh, C.
Howard, D.
Dole, W. P.
机构：
[1] Novartis Pharmaceut Corp, E Hanover, NJ USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Novartis Inst Biomed Res, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [1] Lack of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and celecoxib in healthy volunteers.
    Agarwal, A.
    Vaidyanathan, S.
    Dieterich, H. A.
    Yeh, C.
    Howard, D.
    Dole, W. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S109 - S110
  • [2] Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: A study in healthy volunteers.
    Zhao, C.
    Vaidyanathan, S.
    Dieterich, H. A.
    Yeh, C.
    Howard, D.
    Dole, W. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S110 - S110
  • [3] Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers.
    Dieterich, H
    Kemp, C
    Vaidyanathan, S
    Yeh, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P12 - P12
  • [4] ASSESSMENT OF THE PHARMACOKINETIC INTERACTION BETWEEN FIMASARTAN AND LINAGLIPTIN IN HEALTHY VOLUNTEERS.
    Seong, S.
    Kang, W.
    Ohk, B.
    Kim, B.
    Gwon, M. -R.
    Cho, S.
    Lee, H.
    Yoon, Y. -R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S70 - S70
  • [5] A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects
    Vaidyanathan, Sujata
    Maboudian, Mojdeh
    Warren, Vance
    Yeh, Ching-Ming
    Dieterich, Hans Armin
    Howard, Dan
    Dole, William P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (08) : 2313 - 2326
  • [6] Aliskiren, an oral direct renin inhibitor, has no effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang, H. A.
    Vaidyanathan, S.
    Yeh, C.
    Dieterich, H. A.
    Dole, W. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S59 - S60
  • [7] Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers.
    Vaidyanathan, S
    Limoges, D
    Yeh, C
    Dieterich, H
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P64 - P64
  • [8] PHARMACOKINETIC INTERACTION BETWEEN ROSUVASTATIN AND FENOFIBRATE IN HEALTHY VOLUNTEERS.
    Yi, S.
    Kim, M.
    Han, S.
    Park, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S62 - S62
  • [9] Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers
    Waldmeier, Felix
    Glaenzel, Ulrike
    Wirz, Bernard
    Oberer, Lukas
    Schmid, Dietmar
    Seiberling, Michael
    Valencia, Jessica
    Riviere, Gilles-Jacques
    End, Peter
    Vaidyanathan, Sujata
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (08) : 1418 - 1428
  • [10] Pharmacokinetic study on the interaction between cabergoline and clarithromycin in healthy volunteers.
    Nomura, T
    Zhang, J
    Nakatsuka, A
    Nomoto, M
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 74P - 74P
12345